KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Acquisitions (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Acquisitions for 15 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • On a quarterly basis, Acquisitions rose 3531.91% to $1.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.9 billion, a 81.93% decrease, with the full-year FY2025 number at $3.9 billion, down 81.93% from a year prior.
  • Acquisitions was $1.7 billion for Q4 2025 at Bristol Myers Squibb, down from $1.9 billion in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $20.1 billion in Q1 2024 to a low of $35.0 million in Q1 2021.
  • A 5-year average of $1.6 billion and a median of $357.0 million in 2021 define the central range for Acquisitions.
  • Peak YoY movement for Acquisitions: skyrocketed 25608.97% in 2024, then crashed 99.61% in 2025.
  • Bristol Myers Squibb's Acquisitions stood at $152.0 million in 2021, then dropped by 23.68% to $116.0 million in 2022, then surged by 400.86% to $581.0 million in 2023, then plummeted by 91.91% to $47.0 million in 2024, then surged by 3531.91% to $1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Acquisitions are $1.7 billion (Q4 2025), $1.9 billion (Q3 2025), and $285.0 million (Q2 2025).